Abbas, Hussein A. http://orcid.org/0000-0003-2946-3562
Hao, Dapeng http://orcid.org/0000-0002-9043-371X
Tomczak, Katarzyna
Barrodia, Praveen http://orcid.org/0000-0001-7932-2325
Im, Jin Seon
Reville, Patrick K.
Alaniz, Zoe http://orcid.org/0000-0002-9424-5417
Wang, Wei
Wang, Ruiping
Wang, Feng
Al-Atrash, Gheath
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Ning, Jing
Ding, Maomao
Beird, Hannah C. http://orcid.org/0000-0002-5078-534X
Mathews, Jairo T.
Little, Latasha
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Basu, Sreyashi http://orcid.org/0000-0002-5028-3833
Konopleva, Marina http://orcid.org/0000-0002-9347-2212
Marques-Piubelli, Mario L. http://orcid.org/0000-0002-6324-2096
Solis, Luisa M. http://orcid.org/0000-0002-1253-630X
Parra, Edwin Roger http://orcid.org/0000-0001-9068-1636
Lu, Wei
Tamegnon, Auriole
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Green, Michael R. http://orcid.org/0000-0001-6309-9472
Sharma, Padmanee http://orcid.org/0000-0003-4658-055X
Allison, James P.
Kornblau, Steven M. http://orcid.org/0000-0002-5990-9548
Rai, Kunal http://orcid.org/0000-0003-2321-6894
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Daver, Naval
Futreal, Andrew http://orcid.org/0000-0001-8663-2671
Article History
Received: 15 January 2021
Accepted: 27 September 2021
First Online: 18 October 2021
Competing interests
: K.Ta. reports consulting and advisory roles for Symbio Pharmaceuticals, Novartis, GSK and Celgene/BMS. G.A. reports consulting fees from Novartis and Poseida therapeutics, and research funding from Merck and Jenssen Pharmaceuticals. M.R.G. reports consulting fees with VeraStem Oncology and stock/ownership interest KDAc Therapeutics. M.K. reports grant support and consulting fees from AbbVie, Genentech, F. Hoffmann La-Roche, Stemline Therapeutics, Forty-Seven, consulting fees from Amgen and Kisoji, grant support from Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, AstraZeneca, Rafael Pharmaceutical, Sanofi, royalties and stock options from Reata Pharmaceutical Inc. P.S. reports consulting, advisory roles, and/or stocks/ownership for Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAtla, BioNTech, Candel Therapeutics, Catalio, Codiak, Constellation, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, Jounce, JSL Health, Lava Therapeutics, Lytix, Marker, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences. J.P.A. reports consulting, advisory roles, and/or stocks/ownership for Achelois, Adaptive Biotechnologies, Apricity, BioAtla, BioNTech, Candel Therapeutics, Codiak, Dragonfly, Earli, Enable Medicine, Hummingbird, ImaginAb, Jounce, Lava Therapeutics, Lytix, Marker, PBM Capital, Phenomic AI, Polaris Pharma, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences. N.D. reports research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, Astellas, Abbvie, Genentech, Novimmune, Amgen, Trovagene, Gilead and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Genentech, Servier, Trillium, Syndax, Trovagene, Astellas, Gilead and Agios. The remaining authors declare no competing interests.